SCHEMBL4265385

SCHEMBL4265385

Cc1cc(-c2ccc3c(c2)OCO3)cc2c1OCC(=O)N2

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 7/20 0.50
PGR P06401 4/20 0.50
NR3C1 P04150 2/20 0.50
MMP12 P39900 1/20 0.46
BRD4 O60885 2/20 0.44
PKM P14618 1/20 0.43
KDM4E B2RXH2 3/20 0.42
ALDH1A1 P00352 2/20 0.42
RAB9A P51151 2/20 0.42
MAPT P10636 1/20 0.41
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
NPC1 O15118 1/20 0.41
PDE3B Q13370 1/20 0.40
PDE3A Q14432 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TSHR P16473 1/20 0.40
PTPRC P08575 1/20 0.40
PARP1 P09874 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4257196 0.84 NR3C2 (0.50) NR3C2PGRNR3C1MMP12KDM4E
SCHEMBL4267784 0.82 PKM (0.59) NR3C2PGRNR3C1MMP12PKM
SCHEMBL4266646 0.82 PGR (0.60) NR3C2PGRNR3C1PDE3BPDE3A
SCHEMBL4263576 0.79 NR3C2 (0.50) NR3C2PGRNR3C1MMP12PKM
SCHEMBL4267401 0.79 PGR (0.49) NR3C2PGRNR3C1MMP12KDM4E
SCHEMBL4264666 0.78 PGR (0.56) NR3C2PGRNR3C1
SCHEMBL4258395 0.78 NR3C2 (0.48) NR3C2PGRNR3C1MMP12BRD4
SCHEMBL4261964 0.77 PGR (0.50) NR3C2PGRNR3C1MMP12KDM4E
SCHEMBL4260391 0.77 PGR (0.48) NR3C2PGRNR3C1MMP12
SCHEMBL4258385 0.77 NR3C2 (0.50) NR3C2PGRNR3C1MMP12KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US claimed
JP-2008508314-A 2008-03-21 JP claimed
EP-1778242-A2 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2007-05-02 EP claimed
WO-2006015259-A2 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2006-02-09 WO claimed
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US disclosed
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS NR5A1, ESRRA, NR3C1 NR3C2 7/4885PGR 46/4885NR3C1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.